Durvalumab and Endocrine Therapy in ER+/Her2- Breast Cancer After CD8+ Infiltration Effective Immune-Attractant Exposure
Status:
Completed
Trial end date:
2020-08-28
Target enrollment:
Participant gender:
Summary
This is an open-label, multicentric, international, phase II trial testing aromatase
inhibitors in combination with durvalumab in patients with CD8+ T cell infiltration (>10%
CD8+ T cells in the tumor). The trial includes two sequences: The first part of the treatment
will consist in 4-6 weeks treatment with immune-attractants; in the second part, CD8+
patients will receive 6 months of durvalumab combined with exemestane.